New ALS drug injected into spine begins human testing

NCT ID NCT07100119

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called LY4256984 in 32 people with sporadic ALS. The drug is injected into the spine to see if it is safe and how the body handles it. The main goal is to check for side effects, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4256984 (given as an injection into the spine)
What this could lead to: If successful, this could point toward a treatment that slows or controls ALS progression.
What could go wrong: This is a very early Phase 1 trial with only 32 people, focused on safety. It is too soon to know if the drug works, and it may cause side effects or fail in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis sporadic amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS - AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Heritage Medical Research Clinic
NOT_YET_RECRUITING

Calgary, T2N4Z6, Canada
Hospital Universitari i Politecnic La Fe
RECRUITING

Valencia, 46026, Spain
Hospital Universitario de Bellvitge
RECRUITING

L'Hospitalet de Llobregat, 8907, Spain
London Health Sciences Centre
NOT_YET_RECRUITING

London, N6A 5A5, Canada
Montreal Neurological Institute and Hospital
RECRUITING

Montreal, H3A 2B4, Canada
Sunnybrook Research Institute
RECRUITING

Toronto, M4N 3M5, Canada
UZ Leuven
RECRUITING

Leuven, 3000, Belgium
Universitair Medisch Centrum Utrecht
RECRUITING

Utrecht, 3584, Netherlands
Universitätsklinikum Schleswig-Holstein
RECRUITING

Lübeck, 23538, Germany
Universitätsklinikum Ulm
NOT_YET_RECRUITING

Ulm, 89081, Germany
Universitätsmedizin Rostock Sektion für Translationale Neurodegeneration "Albrecht Kossel" Klinik und Poliklinik für Neurologie
NOT_YET_RECRUITING

Rostock, 18147, Germany
Walter Mackenzie Health Sciences Centre
NOT_YET_RECRUITING

Edmonton, T6G 2X8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.